热门文章

• 

  3D Medicines Announces that the IND of Batiraxcept+Envafolimab/Lenvatinib for Advanced Solid Tumor Cancer was Approved by NMPA

  2022-04-18 08:30:00
• 

  3D Medicines Inc. Announces that the IND for Phase 1 Clinical Trial to Evaluate 3D189 (Galinpepimut-S), a peptide cancer vaccine, was approved by NMPA

  2022-04-06 19:00:00
• 

  3D Medicines and Merck Reach Clinical Research Collaboration to Explore Combination of Immuno-oncology Treatment with Targeted Therapy in Metastatic Colorectal Cancer

  2022-03-14 02:00:00
• 

  3D Medicines Inc，Announces that the IND for Phase 1 Clinical Trial to Evaluate 3D197 (IMC-002), a of CD47 Antibody Drug, was approved by NMPA

  2022-01-12 00:00:00
• 

  Envafolimab, The PD-L1 Antibody Approved by NMPA! 3DMed Partners with Alphamab Oncology and Simcere to Innovate Immunotherapy

  2021-11-26 00:00:00